Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Sales-type lease selling price

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:SalesTypeLeaseRevenue.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's sales-type lease selling price.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's sales-type lease selling price?
Charles River Laboratories (CRL) reported sales-type lease selling price of $12.2M in Q1 2026.
How has Charles River Laboratories's sales-type lease selling price changed year-over-year?
Charles River Laboratories's sales-type lease selling price increased by 5.2% year-over-year, from $11.6M to $12.2M.
What is the long-term trend for Charles River Laboratories's sales-type lease selling price?
Over 2 years (2023 to 2025), Charles River Laboratories's sales-type lease selling price has grown at a -27.5% compound annual growth rate (CAGR), from $93.1M to $49M.